| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Ordinary Shares |
| (b) | Name of Issuer:
CytoMed Therapeutics Ltd |
| (c) | Address of Issuer's Principal Executive Offices:
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore,
SINGAPORE
, 149544. |
| Item 2. | Identity and Background |
|
| (a) | Choo Chee Kong |
| (b) | 1 Commonwealth Lane #08-22, Singapore 149544 |
| (c) | The Reporting Person is the Chairman of the Board and Director of the Issuer. The address of the Issuer is 1 Commonwealth Lane #08-22, Singapore 149544 |
| (d) | No |
| (e) | No |
| (f) | Singapore |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | PF; Between October 5, 2026 and October 8, 2026, the Reporting Person acquired an aggregate of 62,000 Ordinary Shares in open market purchases on the Nasdaq Capital Market for an aggregate purchase price of approximately $60,554.03, settled through the Reporting Person's brokerage account with personal funds. |
| Item 4. | Purpose of Transaction |
| | Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:
the Reporting Person beneficially owns 2,974,746 Ordinary Shares, representing 24.92% of the Issuer's outstanding shares as of the date hereof.
This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 194,112 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 705,324 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,934,908 Ordinary Shares outstanding as of the date hereof. |
| (b) | Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 899,436 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares. |
| (c) | Between October 5, 2026 and October 8, 2026, the Reporting Person acquired an aggregate of 62,000 Ordinary Shares of the Issuer in open market purchases on the Nasdaq Capital Market, effected through a brokerage account, as follows: (i) 44,000 Ordinary Shares on October 5, 2026, at a weighted average price of $0.9899 per share, in multiple transactions at prices ranging from $0.9080 to $1.0458 per share; (ii) 3,500 Ordinary Shares on October 6, 2026, at a weighted average price of $0.9132 per share, in multiple transactions at prices ranging from $0.8805 to $0.9483 per share; (iii) 11,000 Ordinary Shares on October 7, 2026, at a weighted average price of $0.9544 per share, in multiple transactions at prices ranging from $0.9158 to $0.9799 per share; and (iv) 3,500 Ordinary Shares on October 8, 2026, at a weighted average price of $0.9443 per share, in multiple transactions at prices ranging from $0.9426 to $0.9450 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the ranges set forth above. All such transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5 under the Securities Exchange Act of 1934, as amended. |
| (d) | None |
| (e) | N/A |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | The Reporting Person and the remaining shareholders of Glorious Finance Limited may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions.
Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6. |
| Item 7. | Material to be Filed as Exhibits. |
| | Except as set forth herein, there are no material agreements, contracts, arrangements, or understandings that require filing as exhibits under this Item 7. |
